References

A history of cancer chemotherapy

10.1158/0008-5472.can-07-6611 · 2008 · External reference

Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline

10.1200/jco.20.03399 · 2021 · External reference

Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases

10.1002/bjs.10572 · 2017 · External reference

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

10.1038/s41591-018-0198-0 · 2018 · External reference

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

10.1038/s41591-020-01224-2 · 2021 · External reference

Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer

10.1056/nejmoa2202170 · 2022 · External reference

LBA6 Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)

10.1016/j.annonc.2022.08.039 · 2022 · External reference

Neoadjuvant relatlimab and nivolumab in resectable melanoma

2022 · External reference

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial

10.1016/s2468-1253(21)00385-x · 2022 · External reference

Unresolved reference

External reference

Venous thromboembolism after major cancer surgery: temporal trends and patterns of care

10.1001/jamasurg.2013.3172 · 2014 · External reference

Extended versus conventional thromboprophylaxis after major abdominal and pelvic surgery: Systematic review and meta-analysis of randomized clinical trials

10.1016/j.surg.2018.05.028 · 2018 · External reference

Trousseau’s syndrome: multiple definitions and multiple mechanisms

10.1182/blood-2006-10-053736 · 2007 · External reference

Prevention of venous thromboembolism in patients with cancer

2023 · External reference

Thromboembolic events associated with bevacizumab plus chemotherapy for patients with colorectal cancer: a meta-analysis of randomized controlled trials

2016 · External reference

Factors associated with adverse cardiovascular events in cancer patients treated with bevacizumab

10.3390/jcm9082664 · 2020 · External reference

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

10.1093/annonc/mdx514 · 2017 · External reference

Aflibercept

10.1158/1078-0432.ccr-12-2911 · 2013 · External reference

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

10.1200/jco.2012.42.8201 · 2012 · External reference

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer

10.1056/nejmoa1406470 · 2015 · External reference

Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery

2018 · External reference

Preoperative thrombocytopenia and postoperative outcomes after noncardiac surgery

10.1097/aln.0b013e3182a4441f · 2014 · External reference

Perioperative thrombocytopenia: evidence, evaluation, and emerging therapies

10.1016/j.bja.2018.09.010 · 2019 · External reference

Surgical treatment of acute abdominal complications in hematology patients: outcomes and prognostic factors

10.1080/10428194.2017.1296145 · 2017 · External reference

Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer

10.1056/nejmoa1611310 · 2016 · External reference

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

10.1016/s0140-6736(17)32440-6 · 2017 · External reference

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

10.1016/s1470-2045(17)30469-2 · 2017 · External reference

Exploring and comparing adverse events between PARP inhibitors

10.1016/s1470-2045(18)30786-1 · 2019 · External reference

Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer

10.1111/ajco.12636 · 2016 · External reference

Risk of thrombocytopenia with platelet-derived growth factor receptor kinase inhibitors in cancer patients: a systematic review and meta-analysis of phase 2/3 randomized, controlled trials

10.1002/jcph.1938 · 2021 · External reference

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

10.1056/nejmoa1303989 · 2013 · External reference

Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy

10.1056/nejmoa1611406 · 2016 · External reference

Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis

10.18632/oncotarget.10019 · 2016 · External reference

Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy

10.1111/jth.15354 · 2021 · External reference

Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM

10.1002/ijc.34495 · 2023 · External reference

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

10.1056/nejmoa020461 · 2002 · External reference

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033

10.1200/jco.2007.13.4452 · 2008 · External reference

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors

10.6004/jnccn.2010.0116 · 2010 · External reference

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

10.1016/s0140-6736(04)17098-0 · 2004 · External reference

Hematological immune related adverse events after treatment with immune checkpoint inhibitors

10.1016/j.ejca.2021.01.013 · 2021 · External reference

Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival

10.1007/s00262-021-03068-2 · 2022 · External reference

Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials

10.18632/oncotarget.12926 · 2017 · External reference

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer

2023 · External reference

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial

10.1016/s1470-2045(17)30043-8 · 2017 · External reference

A population-based study of complications after colorectal surgery in patients who have received bevacizumab

10.1097/dcr.0000000000000966 · 2018 · External reference

Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

10.1371/journal.pone.0243252 · 2020 · External reference

Safety of early bevacizumab administration after central venous port placement for patients with colorectal cancer

10.3390/cancers15082264 · 2023 · External reference

Effect of biologics on the risk of advanced-stage inflammatory bowel disease-associated intestinal cancer: a nationwide study

10.14309/ajg.0000000000002149 · 2023 · External reference

Association of preoperative anti-tumor necrosis factor therapy with adverse postoperative outcomes in patients undergoing abdominal surgery for ulcerative colitis

10.1001/jamasurg.2017.1538 · 2017 · External reference

Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis

10.1016/j.crohns.2013.01.014 · 2013 · External reference

Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept

10.1093/rheumatology/keab438 · 2022 · External reference

Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments

10.1002/art.39761 · 2016 · External reference

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

10.1136/jitc-2021-002435 · 2021 · External reference

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665

10.1002/jso.21160 · 2009 · External reference

Unresolved reference

External reference

Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial

10.1016/s0140-6736(21)00766-2 · 2021 · External reference

Is there any effect of first-day usage of a totally implantable venous access device on complications?

10.1007/s10147-015-0830-7 · 2015 · External reference

Totally implantable venous access port systems and risk factors for complications: a one-year prospective study in a cancer centre

10.1016/j.ejso.2011.06.016 · 2011 · External reference

10.1016/j.ejso.2016.10.020

10.1016/j.ejso.2016.10.020 · 2017 · External reference

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer

10.1136/jitc-2020-001282 · 2020 · External reference

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

10.1186/1756-8722-3-47 · 2010 · External reference

Randomized trial of TAS-102 for refractory metastatic colorectal cancer

10.1056/nejmoa1414325 · 2015 · External reference

Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial

10.1016/s1470-2045(22)00062-6 · 2022 · External reference

Phase II trial of palbociclib in patients with advanced esophageal or gastric cancer

10.1634/theoncologist.2020-0681 · 2020 · External reference

Incidence and risk of severe adverse events associated with trastuzumab emtansine (T-DM1) in the treatment of breast cancer: an up-to-date systematic review and meta-analysis of randomized controlled clinical trials

10.1080/17512433.2022.2121704 · 2022 · External reference